Table 5.
Copeptin Level Reactions in Patients Without IHD in fv, CS, and LA in Both Randomized Groups
| Baseline | 95% CI | 30 Minutes After the Induction | 95% CI | P time×randomization | |
|---|---|---|---|---|---|
| Copeptinint fv (pmol/L) n=27 | 8.23 | 5.34 to 12.7 | 5.9 | 3.94 to 8.85 | 0.003a |
| Copeptincon fv (pmol/L) n=15 | 6.41 | 4.7 to 8.5 | 6.63 | 4.59 to 9.56 | |
| Copeptinint CS (pmol/L) n=24 | 9.04 | 5.64 to 14.5 | 6 | 3.94 to 9.1 | 0.015a |
| Copeptincon CS (pmol/L) n=12 | 6.79 | 5.1 to 9.04 | 6.78 | 4.45 to 10.35 | |
| Copeptinint LA (pmol/L) n=27 | 7.93 | 5.1 to 12.35 | 5.67 | 3.84 to 8.37 | 0.011a |
| Copeptincon LA (pmol/L) n=15 | 6.37 | 4.59 to 8.83 | 6.18 | 4.31 to 8.86 |
Copeptin levels are presented as geometric means with 95% CI. The results from repeated‐measure ANOVA within‐subjectsȧ contrast tests after correction for false discovery rates due to multiple testing. ANOVA indicates analysis of variance; CI, confidence intervals; con, control group; CS, coronary sinus; fv, femoral vein; IHD, ischemic heart disease; int, intervention group; LA, left atrium; n, number of patients available for analysis.
a
Statistical significant P values after correction for false discovery rate.